O
MAKO

OrbiMed’s MAKO SURGICAL CORP COM MAKO Stock Holding History

OrbiMed’s Portfolio MAKO Stock Details MAKO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-2,212,100
Closed -$26.7M – 149
2013
Q2 		$26.7M Buy
+2,212,100
New +$25.1M 0.57% 39

Other funds holding MAKO

OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AAA
Alpine Associates Advisors Englewood Cliffs, New Jersey $158M AUM 48.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

OrbiMed's MAKO Position: Q3 2013 in Review

OrbiMed sold out of MAKO SURGICAL CORP COM (MAKO) in Q3 2013, closing a stake of 2,212,100 shares — an estimated $26.7M sold.

OrbiMed first reported a position in MAKO in Q2 2013 and held it in 1 quarter. The position peaked at $26.7M in Q2 2013. 144 funds tracked by Wall St. Rank hold MAKO as of Q3 2013.

  • OrbiMed reported no remaining MAKO SURGICAL CORP COM position as of Q3 2013 after selling out during the quarter.
  • OrbiMed sold 2,212,100 MAKO SURGICAL CORP COM shares in Q3 2013, an estimated $26.7M.
  • OrbiMed first reported a position in MAKO SURGICAL CORP COM in Q2 2013 and held it in 1 quarter.
  • OrbiMed's MAKO SURGICAL CORP COM position peaked at $26.7M in Q2 2013.
  • 144 funds tracked by Wall St. Rank held MAKO SURGICAL CORP COM as of Q3 2013.

Based on OrbiMed's 13F filing for Q3 2013, filed 14 Nov 2013.